---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-214102"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2021-07-13T23:59:59+00:00"
generated_at: "2026-06-30T05:46:22.215875+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# IMARA files July 2021 corporate presentation on hemoglobin disorder pipeline

## Summary
- Filed a corporate slide presentation as Exhibit 99.1 under Item 8.01.
- Presentation titled 'Advancing Novel Treatments for Hemoglobin Disorders' dated July 2021.
- No financial results, guidance, or material operational updates provided.
- Routine disclosure of materials used in investor meetings; no new events announced.

## SEC filing metadata
- accession: 0001193125-21-214102
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2021-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312521214102/0001193125-21-214102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312521214102/d150922d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-214102
- JSON: https://secwatch.observer/filing/0001193125-21-214102.json
- Plain text: https://secwatch.observer/filing/0001193125-21-214102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.